Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector

被引:26
作者
Fukui, T
Hayashi, Y
Kagami, H
Yamamoto, N
Fukuhara, H
Tohnai, I
Ueda, M
Mizuno, M
Yoshida, J
机构
[1] Nagoya Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Mol Neurosurg, Showa Ku, Nagoya, Aichi 4668550, Japan
[3] Nagoya Univ, Grad Sch Med, Dept Neurosurg, Showa Ku, Nagoya, Aichi 4668550, Japan
来源
ORAL ONCOLOGY | 2001年 / 37卷 / 03期
关键词
squamous cell carcinoma; suicide gene therapy; adeno-associated virus; herpes simplex virus thmidine kinase; ganciclovir;
D O I
10.1016/S1368-8375(00)00093-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to test the possibility of gene transfer as a new therapy for oral cancer. Adeno-associated virus (AAV) has already been used in the fields of cystic fibrosis and Parkinson's disease as a potential vector for gene therapy because of its wide host range, high transduction efficiency, and lack of cytopathogenicity. Four human oral squamous cell carcinoma cell lines were transduced with an AAV vector containing the P-galactosidase gene (AAVlacZ) in vitro. Gene transduction efficiency was from 20 to 50% at a multiplicity of infection (MOI; for the purposes of this study the number of vector genomes per target cell) of 1 x 10(3), and nearly 100% of each cell line were transduced at an MOI of 1 x 10(4). Next, four cell lines were transduced with an AAV vector containing the herpes simplex virus thymidine kinase (HSVtk) gene, which sensitizes transduced cells to ganciclovir (GCV). Subsequent administration of GCV resulted in nearly 100% tumor cell killing at an MOI of 1 x 10(4) and from 70 to 80% tumor cell killing at an MOI of 1 x 10(3). These results suggest that AAV-mediated gene transfer of HSVtk and administration of GCV has potential as a new therapy for oral squamous cell carcinoma. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:211 / 215
页数:5
相关论文
共 21 条
[1]   GENE-THERAPY FOR CANCER [J].
ANDERSON, WF .
HUMAN GENE THERAPY, 1994, 5 (01) :1-2
[2]   DEVELOPMENT OF ANTITUMOR IMMUNITY FOLLOWING THYMIDINE KINASE-MEDIATED KILLING OF EXPERIMENTAL BRAIN-TUMORS [J].
BARBA, D ;
HARDIN, J ;
SADELAIN, M ;
GAGE, FH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (10) :4348-4352
[3]   ADENOASSOCIATED VIRUSES - AN UPDATE [J].
BERNS, KI ;
BOHENZKY, RA .
ADVANCES IN VIRUS RESEARCH, 1987, 32 :243-306
[4]   IN-VITRO EVIDENCE THAT METABOLIC COOPERATION IS RESPONSIBLE FOR THE BYSTANDER EFFECT OBSERVED WITH HSV TK RETROVIRAL GENE-THERAPY [J].
BI, WL ;
PARYSEK, LM ;
WARNICK, R ;
STAMBROOK, PJ .
HUMAN GENE THERAPY, 1993, 4 (06) :725-731
[5]   GENE-THERAPY FOR HEAD AND NECK-CANCER [J].
CLAYMAN, GL .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1995, 17 (06) :535-541
[6]   INVIVO GENE-TRANSFER WITH RETROVIRAL VECTOR PRODUCER CELLS FOR TREATMENT OF EXPERIMENTAL BRAIN-TUMORS [J].
CULVER, KW ;
RAM, Z ;
WALLBRIDGE, S ;
ISHII, H ;
OLDFIELD, EH ;
BLAESE, RM .
SCIENCE, 1992, 256 (5063) :1550-1552
[7]  
FREEMAN SM, 1993, CANCER RES, V53, P5274
[8]   PROSPECTS FOR THE USE OF ADENOASSOCIATED VIRUS AS A VECTOR FOR HUMAN GENE-THERAPY [J].
KOTIN, RM .
HUMAN GENE THERAPY, 1994, 5 (07) :793-801
[9]  
LIU TJ, 1994, CANCER RES, V54, P3662
[10]   Adeno-associated virus vectors can be efficiently produced without helper virus [J].
Matsushita, T ;
Elliger, S ;
Elliger, C ;
Podsakoff, G ;
Villarreal, L ;
Kurtzman, GJ ;
Iwaki, Y ;
Colosi, P .
GENE THERAPY, 1998, 5 (07) :938-945